Platform Differentiator Azitra’s engineered Staphylococcus epidermidis live biotherapeutic platform and a library of about 1500 bacterial strains provide a unique, modular approach to dermatology programs that could attract licensing or co-development deals with big pharma seeking microbiome-based therapies.

Rare Disease Focus ATR-12 for Netherton syndrome and ATR-04 for EGFR inhibitor–associated skin toxicity target high-need orphan and dermatology indications, creating clear avenues for strategic partnerships and potential expedited regulatory pathways.

Expanding Pipeline Ongoing work on ATR-01 for ichthyosis vulgaris and planned IND activity offer multiple entry points across stages and indications for collaboration, milestone-driven deals, or joint development initiatives.

Market & Investment Alignment Active engagement in major conferences and a current revenue base signal readiness for co-development or licensing partnerships and potential access to capital to accelerate pipeline partnerships.

Manufacturing & regulatory Live biotherapeutic products require specialized manufacturing and regulatory oversight, presenting opportunities for CDMO-style partnerships, scale-up collaborations, and shared GMP capabilities with larger manufacturers.